Helio Genomics

Executive Summary

Helio Genomics is an AI-driven diagnostics company focused on early cancer detection through non-invasive blood tests. Founded in 2015 and based in Los Angeles, the company leverages advanced genomics and machine learning to analyze cell-free DNA for cancer signals. Its mission is to identify cancer at its earliest, most treatable stages, potentially improving patient outcomes significantly. The company operates in the growing liquid biopsy market, which is gaining traction for its ability to detect multiple cancer types from a simple blood draw. While Helio Genomics is private and has not disclosed funding or valuation, its AI-centric approach positions it as an innovative player in the early detection space. The company's success hinges on validating its technology through clinical studies and navigating the regulatory pathway to commercialization. With increasing awareness of liquid biopsies and AI in healthcare, Helio Genomics has the potential to disrupt traditional cancer screening if its tests demonstrate high sensitivity and specificity.

Upcoming Catalysts (preview)

• 2026Clinical validation data for HelioLiver test60% success
• 2026FDA pre-submission or breakthrough designation40% success
• 2026Strategic partnership or licensing deal50% success